Literature DB >> 20975016

Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review.

Alfonso Iorio1, Clive Kearon, Esmeralda Filippucci, Maura Marcucci, Ana Macura, Vittorio Pengo, Sergio Siragusa, Gualtiero Palareti.   

Abstract

BACKGROUND: We aimed to determine the risk of recurrence for symptomatic venous thromboembolism (VTE) provoked by different transient risk factors. DATA SOURCES: MEDLINE, EMBASE, and Cochrane Collaboration Registry of Randomized Trials databases were searched. STUDY SELECTION: Prospective cohort studies and randomized trials of patients with a first episode of symptomatic VTE provoked by a transient risk factor and treated for at least 3 months were identified. DATA EXTRACTION: Number of patients and recurrent VTE during the 0- to 12-month and 0- to 24-month intervals after stopping therapy, study design, and provoking risk factor characteristics were extracted. DATA SYNTHESIS: Annualized recurrence rates were calculated and pooled across studies. At 24 months, the rate of recurrence was 3.3% per patient-year (11 studies, 2268 patients) for all patients with a transient risk factor, 0.7% per patient-year (3 studies, 248 patients) in the subgroup with a surgical factor, and 4.2% per patient-year (3 studies, 509 patients) in the subgroup with a nonsurgical factor. In the same studies, the rate of recurrence after unprovoked VTE was 7.4% per patient-year. The rate ratio for a nonsurgical compared with a surgical factor was 3.0 and for unprovoked thrombosis compared with a nonsurgical factor was 1.8 at 24 months.
CONCLUSIONS: The risk of recurrence is low if VTE is provoked by surgery, intermediate if provoked by a nonsurgical risk factor, and high if unprovoked. These risks affect whether patients with VTE should undergo short-term vs indefinite treatment.

Entities:  

Mesh:

Year:  2010        PMID: 20975016     DOI: 10.1001/archinternmed.2010.367

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  66 in total

Review 1.  Managing pulmonary embolism using prognostic models: future concepts for primary care.

Authors:  Geert-Jan Geersing; Ruud Oudega; Arno W Hoes; Karel G M Moons
Journal:  CMAJ       Date:  2011-12-05       Impact factor: 8.262

Review 2.  Predicting the risk of recurrent venous thromboembolism (VTE).

Authors:  Michael B Streiff
Journal:  J Thromb Thrombolysis       Date:  2015-04       Impact factor: 2.300

Review 3.  Thrombophilia: clinical-practical aspects.

Authors:  Stephan Moll
Journal:  J Thromb Thrombolysis       Date:  2015-04       Impact factor: 2.300

Review 4.  Who should get long-term anticoagulant therapy for venous thromboembolism and with what?

Authors:  Marc Alan Rodger; Gregoire Le Gal
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 5.  Venous thromboembolism: Predicting recurrence and the need for extended anticoagulation.

Authors:  Geoffrey D Barnes; Yogendra Kanthi; James B Froehlich
Journal:  Vasc Med       Date:  2015-04       Impact factor: 3.239

6.  Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Clive Kearon; Elie A Akl; Anthony J Comerota; Paolo Prandoni; Henri Bounameaux; Samuel Z Goldhaber; Michael E Nelson; Philip S Wells; Michael K Gould; Francesco Dentali; Mark Crowther; Susan R Kahn
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

7.  Recurrence risk after anticoagulant treatment of limited duration for late, second venous thromboembolism.

Authors:  Tom van der Hulle; Melanie Tan; Paul L den Exter; Mark J G van Roosmalen; Felix J M van der Meer; Jeroen Eikenboom; Menno V Huisman; Frederikus A Klok
Journal:  Haematologica       Date:  2014-09-26       Impact factor: 9.941

8.  Deep vein thrombosis in a transgender woman.

Authors:  Wesley Chan; Alasdair Drummond; Martina Kelly
Journal:  CMAJ       Date:  2017-04-03       Impact factor: 8.262

Review 9.  Predicting the risk of venous thromboembolism recurrence.

Authors:  John A Heit
Journal:  Am J Hematol       Date:  2012-02-24       Impact factor: 10.047

Review 10.  Direct oral anticoagulants for extended treatment of venous thromboembolism: insights from the EINSTEIN CHOICE study.

Authors:  Davide Imberti; Fulvio Pomero; Daniela Mastroiacovo
Journal:  Blood Transfus       Date:  2019-04-30       Impact factor: 3.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.